GLP-2 “TZ” — 5 mg (3 mL vial, lyophilized peptide)

A 39-amino-acid, acylated dual incretin analog that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors in in-vitro GPCR pharmacology. Lipidation via a long-chain diacid linker enhances albumin association and peptide persistence in cell-based systems. Supplied by Peptide Tech at ≥ 99% purity (HPLC/MS verified) for in-vitro, cellular, and biochemical research use only (RUO). Not for human or veterinary use.

Specifications

CAS Number	2023788-19-2
Chemical Name	Dual GIP/GLP-1 receptor agonist peptide
PubChem CID	156588324
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈ (free base)
Molecular Weight	≈ 4,813.5 g/mol (free base)
Sequence	39-aa dual incretin analog with Aib substitutions at positions 2 and 13; Lys₂₀ acylated via γ-Glu–(AEEA)₂–C₂₀ fatty diacid; C-terminal amide; linear (no disulfides). Exact lot details: see COA.
Counter-ion	Acetate (typical; confirm on lot COA)
Physical Appearance	White to off-white lyophilized powder
Container	3 mL Type I glass vial, bromobutyl rubber stopper, aluminum flip-off seal (net content: 5 mg)
Purity	≥ 99% (verified by HPLC & MS; third-party tested)
Solubility	Soluble in sterile water; for concentrated stocks, pre-wet with ≤0.1–5% acetic acid and gently agitate. Consider 0.05–0.1% carrier protein to minimize adsorption; 0.22 µm filter-sterilize if required.

Molecular Structure (Reference)

Molecular structure of Tirzepatide

Why Peptide Tech

Same-Day Shipping
GMP-Aligned Lyophilized Peptides
USA Made
24/7 Support
Price Match Guarantee
Batch Tracking with QR Code Verification
3rd-Party USA Lab Testing — purity, quantity, endotoxin
Cold-Chain Shipping — Always (no paid upgrade)
Worldwide Shipping
All Major Payments Accepted
Text & Email Order Updates
2-Day FedEx/UPS Shipping Standard
Cheapest Overnight Rates
Largest Variety of Peptides & Bioregulators

Storage & Handling

Lyophilized (unopened): Store at ≤ −20 °C, protected from light and moisture. For long-term archival, ≤ −80 °C is recommended.
After reconstitution: Aliquot into sterile, low-binding tubes; store at ≤ −80 °C. Avoid repeated freeze–thaw cycles.
Handling: Allow vial to reach room temperature before opening to minimize condensation. Use sterile technique and neutral-pH buffers; consider carrier protein to mitigate surface adsorption.
Research Use Only (RUO): Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.

Potential Applications in Research

Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.

GIPR/GLP-1R pharmacology: cAMP accumulation, β-arrestin recruitment, and receptor internalization in engineered cell systems.
Biased signaling & pathway profiling: Quantify relative bias vs. selective GLP-1R or GIPR agonists.
Ligand binding/occupancy: Competition and kinetic studies against mono-agonist comparators.
Receptor cross-talk: Explore co-expressed GLP-1R/GIPR pathway integration and downstream transcriptional signatures.
Formulation/stability: Assess adsorption, aggregation resistance, and excipient impacts under cell-culture conditions.

Citations (PubMed)

Coskun, T., et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept.” Mol Metab, 2018. PMC
Nauck, M. A., & Quast, D. R. “Tirzepatide, a dual GIP/GLP-1 receptor co-agonist.” Diabetes Obes Metab, 2022. PMC
Sun, B., et al. “Structural determinants of dual incretin receptor agonism by tirzepatide.” PNAS, 2022. PNAS
Frias, J. P., et al. “Efficacy and safety of LY3298176, a dual GIP and GLP-1 receptor agonist.” Lancet, 2018. Link

Compliance & RUO Disclaimer

For laboratory research use only (RUO). Not a drug, food, or cosmetic. Not for human or veterinary use. Purchase and use are limited to qualified personnel operating under institutional laboratory guidelines.